Jump to content

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED


ShareCafe
 Share

Recommended Posts

  • 1 month later...
  • Replies 31
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

In reply to: crystal on Tuesday 10/04/07 09:17am

Have been forced to take another look at MVP as the SP has well and truly fallen out of bed (in fact, fallen out of bed, rolled across the room, out onto the landing and is poised rather precariously at the top of the stairs).

 

The half year was a cracker and full of bullish prognostications, however maybe the result contained a bit more pipline stuffing into the new applications rather than hard repeat orders - no idea, just speculating. Changing of the guard in theCEO's chair never helps sentiment and it always takes the new arrival time to settle in, but that period should be well and truly over by now. Director buying on market recently could be a sign that the business is ok - but may not.

 

On balance I think things are taking a little longer than expected and maybe the market is anticipating a small(ish) capital raising to firm up the balance sheet and provide funding o accelerate overseas expansion.

Link to comment
Share on other sites

  • 2 weeks later...
  • 1 month later...
  • 1 month later...
  • 1 year later...

Well this has been a slow motion train wreck....to say the least... but things are now in place for a sustained move IMO.

 

As mentioned at the agm there are three possible important announcements coming possibly by the end of the year - sales to Saudi, FDA clearance for vet sales into the US and inclusion of Penthrox in doctors bags under the PBS. All would be significant events.

 

Profitable, no debt, good cashflows - everything you want to see in the current market and a plausible growth story.

 

Reinstating the buyback and strong director buying points I think to little downside at these levels.

 

Well worth another look for the thrill seeker!

 

Cheers

Link to comment
Share on other sites

  • 7 years later...

of late, MVP is very much a Most Valuable Player. from $1.50 at start 2015 to $6.50 recently. Even paying a dividend 2c ff.

 

the Penthrox story finally seems to be a success after a long period building awareness; it has now got regulatory and marketing approval across Europe; plus looking to go to the USA. Enhanced manufacturing process cutting costs.

 

A second string to their bow - medical devices - is still early days. Bought Avita AVT local respiratory business Breath-a-Tech

 

Market cap $360mill, little debt; PE is astronomical

........ EPS ... DPS

2015 .. 2.6 ... 0

2016 .. 3.9 ... 3.0

2017 .. 7.3 ... 4.1

Link to comment
Share on other sites

  • 11 months later...

in 2016, MYP received approval from the United States Food and Drug Administration to sell a range of its Anti-Static Space Chamber devices, which can be used to help manage asthma and COPD. The group's respiratory products are now sold in more than 7000 US pharmacies.

 

MVP recently gained full insurance reimbursement from every US healthcare fund, which has opened the company to nationwide chains.

 

Now, the biotechnology company has a deal with the world's largest retailer Walmart to supply at least two products from its range of respiratory devices to all of the 4600 Walmart pharmacies. The products will be supplied through pharmaceutical distributor, McKesson Corp. ​Another two products will be supplied to 2100 Walmart stores in the initial rollout. It also announced a similar deal with US Kmart, which operates 1000 pharmacies.

 

"We expect that respiratory business to grow four-fold over the next few years. We expect after-tax profits to reach over $10 million plus over next three years. This is an important part of our business," said the CEO John Sharman. "It is not every day that an Australian company achieves ranging of product with Walmart," he said. "We have a world-class respiratory device product range and we have a significant price advantage over competitor products in the USA. We are confident our USA business will deliver the expected sales growth in the months to come."

Link to comment
Share on other sites

  • 2 years later...
numbers from Medical Development MVP, announced today:

- Gross revenue up 19.3% (compared to FY18) to $21.38 million

- Net revenue up 19.6% to $20.88 million

- Net profit after tax up 327% to $1.04 million

- Operating expenses grew 8% due to marketing and insurance costs as well as employee share payments

- Earnings per share up 293% to 1.61 cents

- Final dividend of 2 cents per share (fully franked), taking total dividend per share for FY19 to 4 cents

- Net tangible asset backing per share (as of June 30 2019) at 5.6 cents, up from negative 17.9 cents at the end of FY18.

 

Medical Developments reported that sales of its flagship Penthrox medicine grew 47% overall, with a 32% rise in Australian sales and a 68% rise in UK sales. Penthrox is yet to be approved by the US Food and Drug Administration (FDA) but hopes to gain approval by the 2023 financial year, pending further trials.

 

Meanwhile, sales of Respiratory Medical Devices grew 62% in the US market, 111% in the Asian market and 9% in the Australian market, but were down 53% in the UK/EU, leading to an overall decline of 5%. The company hopes to reverse its UK/EU declines during FY20.

 

Outlook for MVP

MVP reiterated its goal to make Penthrox the âââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“mainstream analgesic of choice around the worldâââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ÂÂ. Over the coming year, the company expects to complete the rollout of Penthrox in Europe as well as Asian and Middle Eastern markets, whilst progressing with its pending approvals in the US market as well as the Chinese market.

 

Advancing work on âââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“producing other analgesic and pharmaceutical products using the intellectual property that is our new manufacturing processâââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ remains part of MVPâââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’¢Ã¢Ã¢â€š¬Ã…¾Ãƒâ€šÃ‚¢s long-term plans, as well as consolidating and growing Respiratory Device sales in âââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“the USA, Europe and elsewhereâââہ¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ÂÂ.

- but basically hasn't done too much on the share price, since 2016; stubbornly sub $5 still

Link to comment
Share on other sites

  • 4 months later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share


×
×
  • Create New...